 SAN JOSE, Calif., Nov. 02, 2020 GLOBE NEWSWIRE -- AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we NASDAQ: ANPC, a biotechnology company with operations in China and the United States announced today that the Companys investee company in China, Jiangsu AnPac Health Management Co., Ltd. Jiangsu AnPac in which Jiangsu AnPac and AnPac Bio are a Joint Venture with the Company owning 15 equity interest, qualified for COVID-19 nucleic acid tests in the first half of 2020 and received certification from the regulatory authority on October 17, 2020 for COVID-19 nucleic acid tests in Jiangsu AnPacs medical lab in the City of WuXi, Jiangsu Province, China. Jiangsu AnPac has begun to receive samples for paid COVID-19 nucleic acid tests. Recently, AnPac Bio and Jiangsu AnPac have signed an agreement to develop and qualify new COVID-19 test technologies and products, and carry out evaluations at Jiangsu AnPacs medical lab. 